ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Concepts

• vaccines
• janssen
• sars
• advance purchase agreement
• covid-19 vaccine
• viable vaccine
• vaccine candidate ad26
• sars-cov-2
• vaccine vendors
• award of the contract

Location

London

Description

Procurement of Janssen's vaccine candidate Ad26.COV2-S.

Total Quantity or Scope

This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)).

Award Detail

Award Criteria

CPV Codes

• 33651600 - Vaccines

Indicators

• Award on basis of price.

Legal Justification

The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).

Other Information

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.